FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trialResearch in context

FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trialResearch in context

Summary: Background: Currently, assessment of candidate pharmacotherapies in patients with non-alcoholic steatohepatitis (NASH) involves invasive liver biopsy. Non-invasive scores, such as the FibroScan-aspartate aminotransferase (FAST) score, are used to identify candidates for therapy, but their...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Vincent Wai-Sun Wong, Quentin M. Anstee, Louise M. Nitze, Anja Geerts, Jacob George, Victor Nolasco, Mette S. Kjær, Steen Ladelund, Philip N. Newsome, Vlad Ratziu
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	Elsevier 2023-12-01
Σειρά:	EClinicalMedicine
Θέματα:	Biomarkers Clinical trial Non-alcoholic steatohepatitis NASH Semaglutide
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S258953702300487X

Παρόμοια τεκμήρια

Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration
ανά: Evgenia Koureta, κ.ά.
Έκδοση: (2024-02-01)

Semaglutide improves metabolic dysfunction‐associated steatohepatitis: A 10‐year retrospective study
ανά: Parth Shah, κ.ά.
Έκδοση: (2024-02-01)

Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria
ανά: Jae Seung Lee, κ.ά.
Έκδοση: (2022-04-01)

Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
ανά: Magdalena Mazurek, κ.ά.
Έκδοση: (2023-02-01)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
ανά: Alexander Chaidez, κ.ά.
Έκδοση: (2022-11-01)

Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data
ανά: Takeshi Horii, κ.ά.
Έκδοση: (2024-11-01)

Semaglutide for the treatment of obesity
ανά: Rafał Oleszczuk, κ.ά.
Έκδοση: (2022-01-01)

The efficacy of multi‐disciplinary lifestyle modifications in Taiwanese nonalcoholic steatohepatitis patients
ανά: Ming‐Lun Yeh, κ.ά.
Έκδοση: (2024-06-01)

Angiogenic effects of leptin in patients with nonalcoholic steatohepatitis
ανά: Gaafar Nagah, κ.ά.
Έκδοση: (2005-01-01)

Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
ανά: Wesam Bahitham, κ.ά.
Έκδοση: (2024-02-01)

Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials
ανά: Hanna Pulaski, κ.ά.
Έκδοση: (2024-09-01)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
ανά: Takeshi Hatanaka, κ.ά.
Έκδοση: (2021-10-01)

The craze with semaglutide
ανά: Ruby Dhar, κ.ά.
Έκδοση: (2024-06-01)

Dose-dependent erythema nodosum after initiation of semaglutide
ανά: Jeffrey Sobieraj, MD, κ.ά.
Έκδοση: (2024-05-01)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
ανά: Han Na Jung, κ.ά.
Έκδοση: (2022-03-01)

Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
ανά: Wim Verlinden, κ.ά.
Έκδοση: (2020-11-01)

Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis
ανά: Adam Minich, κ.ά.
Έκδοση: (2022-08-01)

Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease
ανά: Youwen Tan, κ.ά.
Έκδοση: (2024-12-01)

Spotlight on the Mechanism of Action of Semaglutide
ανά: Ilias Papakonstantinou, κ.ά.
Έκδοση: (2024-12-01)

Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations
ανά: Camille Pichon, κ.ά.
Έκδοση: (2022-11-01)

Semaglutide in the Treatment of Diabetes and Associated Obesity
ανά: Rafal Makuch, κ.ά.
Έκδοση: (2024-06-01)

A real‐world disproportionality analysis of semaglutide: Post‐marketing pharmacovigilance data
ανά: Yikuan Du, κ.ά.
Έκδοση: (2024-10-01)

A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use
ανά: Abdul Haseeb Hasan, κ.ά.
Έκδοση: (2025-01-01)

The Synthesis of SNAC Phenolate Salts and the Effect on Oral Bioavailability of Semaglutide
ανά: Tovi Shapira-Furman, κ.ά.
Έκδοση: (2024-08-01)

Contractile Effects of Semaglutide in the Human Atrium
ανά: Joachim Neumann, κ.ά.
Έκδοση: (2024-08-01)

Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide
ανά: Peter Bracha, κ.ά.
Έκδοση: (2024-12-01)

Beneficial effects of ginkgetin on improving nonalcoholic steatohepatitis characterized by bulk and single-cell RNA sequencing analysis
ανά: Chaoyang Wang, κ.ά.
Έκδοση: (2023-10-01)

Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice
ανά: Yang Y, κ.ά.
Έκδοση: (2024-03-01)

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
ανά: Shu Niu, κ.ά.
Έκδοση: (2022-12-01)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
ανά: Takahiro Iijima, κ.ά.
Έκδοση: (2023-06-01)

Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western DietSummary
ανά: Souradipta Ganguly, κ.ά.
Έκδοση: (2021-01-01)

Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis
ανά: Nancy Magee, κ.ά.
Έκδοση: (2022-12-01)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
ανά: Mansoor Husain, κ.ά.
Έκδοση: (2020-09-01)

A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
ανά: Shiqin Zhang, κ.ά.
Έκδοση: (2024-04-01)

The Discovery and Development of Liraglutide and Semaglutide
ανά: Lotte Bjerre Knudsen, κ.ά.
Έκδοση: (2019-04-01)

Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
ανά: Louis Talay, κ.ά.
Έκδοση: (2024-10-01)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
ανά: Xiaoyi Chen, κ.ά.
Έκδοση: (2023-03-01)

Unraveling the Beneficial Role of Resveratrol in Fructose-Induced Non-Alcoholic Steatohepatitis with a Focus on the AMPK/Nrf2 Signaling Axis
ανά: Soha S. Zakaria, κ.ά.
Έκδοση: (2025-01-01)

Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network
ανά: David García-Vega, κ.ά.
Έκδοση: (2024-01-01)

Qushi Huayu decoction attenuated hepatic lipid accumulation via JAK2/STAT3/CPT-1A-related fatty acid β-oxidation in mice with non-alcoholic steatohepatitis
ανά: QinMei Sun, κ.ά.
Έκδοση: (2022-12-01)